J. PAUL OETKEN, District Judge

OPINION AND ORDER

:

Plaintiffs Timba Bimont, Sylvia Bethea, Lourdes Rosado, Rosemary Arellano, Brenda Starr, Ronald Brinkley, Wendy Syroka, Dawn Kelley, Serrena Upton, Kendra Angel, and Mark McIntire bring this putative class action against Unilever United States, Inc. ("Unilever"), alleging violations of the consumer protection laws of several states, breach of warranty, negligent misrepresentation, and unjust enrichment. Unilever moves to dismiss this action pursuant to Federal Rule of Civil Procedure 12(b)(6) on the ground that all of the claims are completely preempted by the Food, Drug, and Cosmetic Act ("FDCA"), 21 U.S.C. § 300, et seq., and its accompanying regulations. For the reasons that follow, Unilever's motion is granted.

I. Background

Unilever sells many popular deodorants under the AXE and Degree brands. (Dkt. No. 14, First Amended Complaint ¶¶ 1, 7, 26 ("FAC").) The packaging of these products, according to the FAC, violates the consumer protection laws of New York, New Jersey, California, Florida, Pennsylvania, Ohio, Georgia, Alabama, Indiana, and Oklahoma, and the common law of every state, because it (1) misstates the "actual weight of usable product" in each stick of deodorant; (2) misstates the "total net weight (including usable and unusable portions of deodorant . . .)"; and (3) contains "non-functional slack-fill[, which,] when displayed for sale to Plaintiffs and other reasonable consumers, caused the false impression that there was more product than actually packaged." (Id. ¶ 4 (emphasis omitted).) The individual Plaintiffs are residents of these states who allege that they purchased AXE and Degree products and were deceived by their packaging. (Id. ¶¶ 14-24.)

II. Discussion

Unilever moves to dismiss the FAC on the ground that all of Plaintiffs' causes of action are preempted by federal law, among other grounds. Because the Court concludes that all of the claims are completely preempted, the Court need not, and does not, reach Unilever's other arguments for dismissal.

A. Legal Standards

To survive a motion to dismiss under Rule 12(b)(6), a plaintiff must plead sufficient factual allegations "to state a claim to relief that is plausible on its face." Bell Atl. Corp. v. Twombly, 550 U.S. 544, 570 (2007). A claim is plausible if the well-pleaded factual allegations of the complaint, presumed true, permit the court to "draw the reasonable inference that the defendant is liable for the misconduct alleged." Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009) (citing Twombly, 550 U.S. at 556). "Threadbare recitals of the elements of a cause of action, supported by mere conclusory statements, do not suffice." Id. (citing Twombly, 550 U.S. at 555). Moreover, "[w]here a complaint pleads facts that are 'merely consistent with' a defendant's liability, it 'stops short of the line between possibility and plausibility of entitlement to relief.'" Id. (quoting Twombly, 550 U.S. at 557).

"[T]here is no private right of action to enforce the FDCA." Church & Dwight Co. Inc. v. SPD Swiss Precision Diagnostics, GmbH, No. 14 Civ. 585 (AJN), 2014 WL 2526965, at *7 (S.D.N.Y. June 3, 2014) (citing PhotoMedex, Inc. v. Irwin, 601 F.3d 919, 924 (9th Cir. 2010)). The FDCA is enforced by the United States Food and Drug Administration ("FDA"). See POM Wonderful LLC v. Coca-Cola Co., 134 S. Ct. 2228, 2235 (2014) ("[T]he FDCA and its regulations provide the United States with nearly exclusive enforcement authority, including the authority to seek criminal sanctions in some circumstances" (citing 21 U.S.C. §§ 333(a), 337)); see also 21 U.S.C. § 337(a) ("[A]ll . . . proceedings for the enforcement, or to restrain violations, of [the FDCA] shall be by and in the name of the United States.").

The FDCA explicitly forbids the states to "establish or continue in effect any requirement for labeling or packaging of a cosmetic that is different from or in addition to, or that is otherwise not identical with, a requirement specifically applicable to a particular cosmetic or class of cosmetics under [the FDCA] . . . or the Fair Packaging and Labeling Act." 21 U.S.C. § 379s(a). Similar language forbids non-identical state requirements for over-the-counter ("OTC") drugs. 21 U.S.C. § 379r(a). While states are forbidden from altering the substantive prohibitions applicable to subjects regulated by (or, perhaps, that could be regulated by) the FDA, they are free to create private rights of action under state statutes that impose requirements identical to those of the FDCA. See Astiana v. Hain Celestial Grp., Inc., 783 F.3d 753, 757 (9th Cir. 2015) ("[T]he FDCA does not preempt state laws that allow consumers to sue cosmetics manufacturers that label or package their products in violation of federal standards."); see also Bates v. Dow Agrosciences LLC, 544 U.S. 431, 447 (2005) (holding that similar language in the Federal Insecticide, Fungicide, and Rodenticide Act does not preempt state causes of action for the violation of requirements identical to those under federal law).

Thus, the question here is whether any of Plaintiffs' claims under state law impose requirements "different from or in addition to, or . . . otherwise not identical with, a requirement specifically applicable" to cosmetics or OTC drugs under the FDCA. 21 U.S.C. § 379s (emphasis added); see also Bowling v. Johnson & Johnson, 65 F. Supp. 3d 371, 375 (S.D.N.Y. 2014) ("In the context of OTC drugs, the FDCA expressly preempts state law labeling requirements that are 'different from,' 'addition[al] to,' or 'otherwise not identical with' federal labeling requirements." (brackets in Bowling)).

A state law that applies to drugs or cosmetics is preempted if it imposes a requirement that is not identical to the requirements of the FDCA and the FDA's regulations. But this comes with a caveat: preemption does not preclude a state-law claim if the state requirement is outside the scope of the relevant federal requirements. See Ackerman v. Coca-Cola Co., No. 09 Civ. 395 (JG) (RML), 2010 WL 2925955, at *6 (E.D.N.Y. July 21, 2010) ("[T]here are two ways plaintiffs may escape [the FDCA's] preemptive force: (1) if the plaintiffs' claims seek to impose requirements that are identical to those imposed by the FDCA; or (2) if the requirements plaintiffs seek to impose are not with respect to claims of the sort described in [the Act]."); see also Ault v. J.M. Smucker Co., No. 13 Civ. 3409 (PAC), 2014 WL 1998235, at *3 (S.D.N.Y. May 15, 2014) (holding that a state cause of action regarding the phrase "all natural" is not preempted because "no federal specifications exist here"); In re PepsiCo, Inc., Bottled Water Mktg. & Sales Practices Litig., 588 F. Supp. 2d 527, 538 (S.D.N.Y. 2008) ("Where federal requirements address the subject matter that is being challenged through state law claims, such state law claims are preempted to the extent they do not impose identical requirements."); Vt. Pure Holdings, Ltd. v. Nestle Waters N. Am., Inc., No. CIV.A.03-11465 (DPW), 2006 WL 839486, at *6 (D. Mass. Mar. 28, 2006) ("[W]here no federal requirement exists, preemption does not occur.").

Courts appear to differ on the degree of distinction from federal law that is permissible in this context. On the one hand, some hold that state laws imposing non-identical requirements in areas that the FDA could have regulated are preempted. That is, these decisions have indicated that a state law cause of action is preempted both "when a state law prohibits labeling that is permitted under federal law" as well as when it "prohibits labeling that is not prohibited under federal law." Bowling, 65 F. Supp. 3d at 375. Under this view, "[t]he standard . . . is not whether a state law actively undermines federal law. It is whether state law diverges from federal law at all." Id.; see also Turek v. Gen. Mills, Inc., 662 F.3d 423, 427 (7th Cir. 2011) (Posner, J.) ("The disclaimers that the plaintiff wants added to the labeling of the defendants' [food product] are not identical to the labeling requirements imposed on such products by federal law, and so they are barred."); PepsiCo, 588 F. Supp. 2d at 534 ("[S]tate law causes of action are not preempted where they merely provide a damages remedy for claims premised on a violation of federal law that does not itself provide a private right of action, but are preempted where they impose obligations not imposed by federal law.").

Other cases apply preemption where the state law imposes requirements that are not identical to federal law in an area in which the FDA engages in some regulation. E.g., Astiana, 783 F.3d at 758; Vt. Pure, 2006 WL 839486, at *6. These cases hold that the relevant "scope" of federal law is defined by the FDA's regulatory choices. If the FDA regulates a given subject matter, it preempts all non-identical state laws within that subject matter. But if the FDA says nothing about the subject matter, states are free to regulate.

Finally, at least one court has taken a more permissive approach to the interaction between the FDCA and state consumer protection statutes, holding that they "serve complementary, though somewhat overlapping, roles," whereby the FDCA "constitutes only a floor upon which states can build additional protections." Jovel v. i-Health, Inc., No. 12 Civ. 5614 (JG), 2013 WL 5437065, at *6 (E.D.N.Y. Sept. 27, 2013). This approach applies preemption only where state law requirements plainly conflict with federal requirements—most commonly, where a state law claim would prohibit conduct that is explicitly permitted by federal law.

State claims are preempted, then, if they (1) impose any non-identical requirement on conduct that could be regulated by the FDA (e.g., Bowling, 65 F. Supp. 3d at 376); (2) impose any non-identical requirement on conduct whose subject matter has been regulated by the FDA (e.g., Vt. Pure, 2006 WL 839486, at *6); or (3) impose any conflicting requirement on conduct that has been regulated by the FDA (e.g., Jovel, 2013 WL 5437065, at *6). Compare also Astiana, 783 F.3d at 758 (concluding that a suit that might "require [the defendant] to remove . . . allegedly misleading advertising statements [concerning whether the product is 'All Natural'] from its product labels" would "not run afoul of the FDCA" because "FDA regulations do not require [the defendant] to label its products as 'All Natural'"), with Bowling, 65 F. Supp. 3d at 376 ("For plaintiffs to establish that their state law claims are not preempted, it is insufficient to show that the FDA has not permitted the label . . . . Rather, plaintiffs would need to plead facts suggesting that the FDA has affirmatively prohibited the label." (emphasis omitted)).

As explained further below, Plaintiffs' claims are preempted under the first and second rules. But they would likely survive the third. Thus, although the Court need not, and does not, resolve the tension between the first and second approaches, the Court must address whether or not the third rule is the correct one. It is not correct chiefly because it is inconsistent with the plain language of the FDCA's preemption statute. That statute forbids the states to impose requirements that are not "identical" to those within the scope of federal law. 21 U.S.C. § 379s (emphasis added). If, when determining whether state laws are within the scope of federal law, courts considered "scope" to mean "those areas that the FDA has already specifically regulated," nothing would be left of the word "identical" in this context. Id. States, under the third rule, would be free to pass any requirements: If the FDA has not already imposed them, they would, by definition, be outside the scope of federal law; and if the FDA has already imposed them, they would be identical to federal law. That cannot be right. Accordingly, the Court rejects the third rule.

B. Non-Functional Slack-Fill

Plaintiffs allege that Unilever's deodorants are packaged so as to give the appearance that they contain more deodorant than they actually contain. (FAC ¶¶ 44-45.) Unilever does this, according to Plaintiffs, simply by selling the deodorants in plastic containers that are larger than they functionally need to be. In order for these state law claims to escape preemption by the FDCA, these claims must attempt to impose requirements that are either (1) identical to federal law or (2) outside the scope of federal law.

The FDCA forbids the "misleading" packaging of drugs and cosmetics. See 21 U.S.C. § 362(d). At first glance, Plaintiffs' claim that the deodorants are packaged with "slack-fill" so as to mislead consumers appears to be identical to this law. But Congress also specifically addressed the issue of slack-fill by explicitly authorizing the FDA to enact regulations to "prevent the nonfunctional-slack-fill of packages containing [foods, drugs, or cosmetics]." 15 U.S.C. § 1454(c)(4). Congress specified that such regulations were to be enacted "[w]henever . . . regulations . . . are necessary to prevent the deception of consumers or to facilitate value comparisons as to any consumer commodity." Id. § 1454(c). The FDA proceeded to pass slack-fill regulations, but covered only slack-fill in food products. See 21 C.F.R. § 100.100 (defining slack-fill as "the difference between the actual capacity of a container and the volume of product contained therein"). These regulations specifically address the permissible reasons for including slack-fill in food packaging, but they say nothing about drug and cosmetics packaging. Id. The question, then, is whether this constitutes an FDA determination that slack-fill in drug and cosmetic packaging is permissible, which would preempt the claims because they impose a non-identical requirement, or whether slack-fill in drug and cosmetic packaging is outside the scope of federal requirements, which would allow the claims to proceed.

The parties do not squarely address this question. (Compare Dkt. No. 22, Plaintiffs' Memorandum of Law in Opposition ["Opposition"], at 14-15, with Dkt. No. 7, Defendant's Reply Memorandum of Law ["Reply"], at 7.) But, given the prevailing case law on FDCA preemption, it is clear that the FDA has regulated slack-fill (which is the relevant "subject matter"), but has declined to interpret the general misbranding statute so as to cover slack-fill in drugs and cosmetics.

Comparing Bowling, PepsiCo, Ault, and Astiana is instructive. In Bowling, Judge Scheindlin addressed allegations that Johnson & Johnson misled consumers when it said that Listerine mouthwash "[r]estores [e]namel" in teeth. Bowling, 65 F. Supp. 3d at 373. Judge Scheindlin held that a state law cause of action for misbranding based on the "restores enamel" claim was preempted by federal law because the FDA had previously issued guidance allowing OTC drug manufactures "(1) to represent that . . . drugs [containing fluoride] prevent tooth decay and (2) to provide further labeling to explain how decay is prevented." Id. The FDA, according to Judge Scheindlin, had addressed the subject matter of fluoride's relationship to tooth decay and had declined to prohibit statements that fluoride restores enamel in teeth. Id. at 376-77. Therefore, the states were not free to prohibit those statements.

In PepsiCo, Judge Seibel addressed allegations that Pepsi had misbranded Aquafina bottled water—which, the plaintiffs alleged, was purified tap water—by including mountainous scenes on its labels, leading to the false impression that the water came from a mountainous source. PepsiCo, 588 F. Supp. 2d at 529. The FDA, according to Judge Seibel, issued specific guidance regarding the disclosure of the source of other types of bottled water—"artesian water," "ground water," "mineral water," and "spring water," 21 C.F.R. § 165.110(a), for example—but not "purified" water. PepsiCo, 588 F. Supp. 2d at 535. Judge Seibel held that the claims were preempted because they imposed a non-identical requirement that was within a subject matter that the FDA had addressed. See id. at 538 ("Where federal requirements address the subject matter that is being challenged through state law claims, such state law claims are preempted to the extent they do not impose identical requirements.").

In Ault, Judge Crotty addressed allegations that Smuckers had misbranded Crisco shortening by labeling it "All Natural." Ault, 2014 WL 1998235, at *1. But Judge Crotty found that this claim was not preempted (unlike the claims in Bowling and PepsiCo) because "the FDA has declined to consider the specific issue here: 'whether and under what circumstances food products containing ingredients produced using genetically engineered ingredients may or may not be labeled "natural."'" Id. at *3 (quoting informal FDA guidance); see also Astiana, 783 F.3d at 758 ("Hain finally points out that the FDA has never issued regulations regarding the use of 'natural' on cosmetics labels. That is true, but Hain then argues that the FDA's failure to issue specific regulations on the subject is tantamount to a conscious decision by the agency to permit any use of this term a manufacturer sees fit. This argument proves too much. By this logic, a manufacturer could make any claim—wild, untruthful, or otherwise—about a product whose contents are not addressed by a specific regulation. The statute, however, proscribes statements that are 'false or misleading in any particular,' not statements that are 'prohibited by specific FDA regulations.'").

The situation here is more like Bowling and PepsiCo than it is like Ault and Astiana. Here, the FDA was given a specific invitation to regulate slack-fill in foods, drugs, and cosmetics, but chose to regulate only slack-fill in foods. Under a strict approach to FDCA preemption, this is sufficient to bar Plaintiffs' claims: A state rule forbidding non-functional slack-fill in drugs and cosmetics would impose a requirement that is in addition to or not identical with federal law, and it would do so on a subject matter that clearly could be regulated by the FDA. But even under the more lenient approach, Plaintiffs' claim still fails. The FDA's failure to regulate in this area constitutes strong evidence that the FDA considered the issue of slack-fill in drugs and cosmetics and decided that slack-fill in those products is insufficiently misleading to warrant regulation. It is, in other words, "tantamount to a conscious decision by the agency to permit" slack-fill. Astiana, 783 F.3d at 758. Similarly, the fact that Congress specifically mentioned slack-fill apart from its general prohibition on misbranding suggests that Congress considered slack-fill an issue specifically to be addressed by the FDA and not merely an instance of misbranding. Accordingly, Plaintiffs' non-functional slack-fill claims are dismissed.

C. Total Net Weight

Plaintiffs next contend that the net weight statements on Unilever's deodorants are false. (FAC ¶ 41.) Unilever argues that the alleged discrepancies between the actual net weight and listed net weight on its products fall within the permissible range established by federal law. (Dkt. No. 20, Memorandum of Law in Support of Defendant's Motion to Dismiss ["Support"], at 10-11.) The FDCA allows for "reasonable variations" in weight, 21 U.S.C. § 362(b), and the National Institute of Standards and Technology ("NIST"), which regulates the permissible variation in this context, has established precise standards for what is and is not reasonable. Plaintiffs concede that the NIST standards apply (Opposition, at 14) and that Unilever's products fall within the reasonable variance interval established by NIST. But Plaintiffs contend that, "[w]hile [Unilever] is correct in stating that the [NIST] permits net weight variation in products, nothing in the regulations contemplates intentional and systematic underfilling as alleged in Plaintiffs' Complaint." (Id. (emphasis omitted).)

The question, then, is whether federal law, which allows for variations within a certain interval, nonetheless prohibits the same variations where they are claimed to be "intentional" and "systematic." In support of their claims, Plaintiffs cite only Torres v. JC Penney Corp., No. 12 Civ. 1105 (JST), 2013 WL 1915681 (N.D. Cal. May 8, 2013), and State of Fla. Office of Atty. Gen.v. Tenet Healthcare Corp., 420 F. Supp. 2d 1288, 1294 (S.D. Fla. 2005). The former case concerns whether the applicability of safe harbors created by California state law, in a case concerning jewelry coatings, can be decided on a motion to dismiss. See Torres, 2013 WL 1915681, at *4. It does not address whether state consumer protection laws are barred by federal preemption in circumstances like those at issue here. The latter case concerns Medicare preemption and concludes that "there is no indication that Congress intended to preempt state law causes of action through the implementation of the Medicare Act." Tenet, 420 F. Supp. 2d at 1298. For this reason, Tenet declined to dismiss state law claims for the "upcoding" of Medicare reimbursement claims. Id. It says nothing about whether federal law allows a manufacturer of drugs and cosmetics deliberately to reduce—assuming that Unilever's alterations are deliberate—the net weight of its products, so long as the result stays within the NIST range.

Plaintiffs, then, have identified nothing in federal law to suggest that manufacturers cannot do what they allege that Unilever has done. Neither has the Court. And, in Jones v. Rath, 430 U.S. 519 (1977), the Supreme Court held that a California rule permitting certain net weight variations in meat was preempted by federal law because it did not allow for "loss of weight resulting from moisture loss during the course of good distribution practice," which USDA regulations permitted. Id. at 530-32. Analogously, then, state laws forbidding net weight variations that are within the range allowed by federal law ought to be preempted as well, even if those variations are intentional or systematic.

Similarly, in Carrea v. Dreyer's Grand Ice Cream, Inc., 475 F. App'x 113, 115 (9th Cir. 2012) (memorandum disposition), the Ninth Circuit concluded that a state-law cause of action regarding a product labeled as containing "0g Trans Fat" that contained more than zero but less than 0.5 grams of trans fat could not survive FDCA preemption. The FDA required that a product "contain[ing] less than 0.5 grams of trans fat per serving" to "express this amount as zero." Id. Presumably that court, and several district courts dealing with the identical issue, considered and rejected the obvious possibility that food companies were deliberately keeping the trans fats in their foods below half a gram in order to avoid reporting that the foods contained trans fat. Cf. Red v. Kroger Co., No. 10 Civ. 1025 (DMG) (MANX), 2010 WL 4262037, at *3 (C.D. Cal. Sept. 2, 2010); Chacanaca v. Quaker Oats Co., 752 F. Supp. 2d 1111, 1119 (N.D. Cal. 2010). The mere fact (or allegation) that underfilling is intentional ought not to control the outcome. Unilever's motion to dismiss the total net weight claims is therefore granted.

D. Usable Net Weight

Plaintiffs claim that the net weight labeling on Unilever's deodorants is misleading because some of the deodorant is "embedded under the plastic platform ('bed') on which the deodorant sticks stand" and is thus unusable. (FAC ¶ 39.) Unilever argues that, to the extent that Plaintiffs plead a violation of state law, the claim is preempted because federal law requires only that manufacturers disclose no more than the weight of the product exclusive of its packaging. (Support, at 7-9.) See 15 U.S.C. § 1461 (stating that it is "the express intent of Congress to supersede any and all laws of the States . . . insofar as they . . . provide for the labeling of the net quantity of contents of the package of any consumer commodity . . . which . . . require information different from" federal law and regulations). Plaintiffs concede that federal law does not explicitly require that "usable" net weight be disclosed. (Opposition, at 10-11.) Instead, they argue that the FDCA allows manufacturers to supplement their net weight labels, and that the FDCA requires packaging to "enable consumers to obtain accurate information as to the quantity of the contents and . . . [to] facilitate value comparisons." (Id. (quoting 15 U.S.C. § 1451).)

But neither of these contentions supports Plaintiffs' case. The mere fact that federal law allows more detail does not mean that it requires more detail. Under the stricter approach to FDCA preemption, this alone dooms Plaintiffs' claim, since the FDA could have regulated in this area. See Bowling, 65 F. Supp. 3d at 376. And even under the more lenient approach, Plaintiffs' usable net weight claim fails. The FDA has promulgated regulations in the area of net weight disclosures for drugs and cosmetics, see 21 C.F.R. § 201.62(a), (f); § 701.13(a), and has decided not to require usable net weight disclosures. As such, at least one court has persuasively rejected the claim that Plaintiffs press here. See Ebner v. Fresh Inc., No. SACV 13-00477 (JVS), 2013 WL 9760035, at *6 (C.D. Cal. Sept. 11, 2013); see also Bowling, 65 F. Supp. 3d at 376-77 (concluding, where the FDA had issued requirements "directly on point but declined, in spite of that, to indicate" that a particular type of labeling was impermissible, that the FDA had determined that such labeling was not misleading). Plaintiffs attempt to distinguish Ebner on the ground that they allege that the total net weight of the deodorants is false, an allegation that the Ebner plaintiffs did not make. But that is a separate claim, which has already been dismissed on other grounds. Plaintiffs' usable net weight claim is, accordingly, also dismissed.

E. Other Claims

Finally, Plaintiffs contend that Unilever falsely advertised its deodorants, and also assert several claims under state common law, including (1) that Unilever breached express warranties included on the product packaging; (2) that Unilever made negligent misrepresentations through its product labeling; and (3) that Unilever was unjustly enriched by misleading representations on its product labeling.

A false advertising claim likely would not be preempted if it was based on advertising apart from the product labeling or packaging. This is because the FDCA does not cover non-label advertising; it covers only the labeling of consumer products. See Jovel, 2013 WL 5437065, at *5 (holding that "consumer protection claims founded on the[] falsity [of statements made in advertising] are not preempted" by the FDCA); Jackson v. Balanced Health Prods., Inc., No. 08 Civ. 5584 (CW), 2009 WL 1625944, at *4 (N.D. Cal. June 10, 2009) ("The existence of the FDCA does not completely preclude injured parties from asserting claims of . . . false advertising."). But Plaintiffs have not pleaded facts sufficient to give rise to the inference that any of Unilever's non-labeling advertisements are false. Indeed, Plaintiffs have not pleaded the content of any of Unilever's non-labeling advertisements, let alone facts demonstrating the falsity of those advertisements or reliance on them. All of Plaintiffs' well-pleaded factual allegations relate to "labeling" and "packaging." Accordingly, Plaintiffs' false-advertising claims are dismissed.

And Plaintiffs' warranty, negligent misrepresentation, and unjust enrichment claims are preempted for essentially the same reason that their state law false advertising claims are. Common law torts constitute "requirements" within the meaning of FDCA preemption. See Bates, 544 U.S. at 443 ("[T]he term 'requirements' . . . reaches beyond positive enactments, such as statutes and regulations, to embrace common-law duties."). Under either version of the governing legal standard discussed above, federal law preempts these causes of action. See Horowitz v. Stryker Corp., 613 F. Supp. 2d 271, 285 (E.D.N.Y. 2009). Plaintiffs' remaining claims are therefore also dismissed.

F. Leave to Amend

In a footnote in their opposition brief, Plaintiffs request leave to amend in the event that Unilever's motion is not denied in its entirety. (Opposition, at 25 n.9.) All of Plaintiffs' claims relate to the "labeling" and "packaging" of Unilever's products, and, for the reasons explained above, such claims are preempted by federal law. Because repleading such claims would not alter that legal conclusion, the Court concludes that amendment would be futile. Leave to amend is therefore denied.

III. Conclusion

For the foregoing reasons, Unilever's motion to dismiss the First Amended Complaint pursuant to Rule 12(b)(6) is GRANTED.

The Clerk of Court is directed to close the motion at docket number 18.

SO ORDERED. Dated: September 9, 2015

New York, New York

/s/_________

J. PAUL OETKEN

United States District Judge